Enzymatics to Sell NGS Diagnostic Tests
The acquisition allows Enzymatics to expand its NGS business to selling diagnostic tests. According to Enzymatics, ArcherDx’s technology has advantages for CNV and translocation analyses, resulting in faster results. According to xconomy.com, Enzymatics had 2012 revenues of $25 million.
Beverly, MA and Boulder, CO 9/6/13—Enzymatics, a producer of reagents, kits and assays, has acquired ArcherDx, a developer of kits and software for next generation sequencing (NGS) for use in investigating cancer treatments, for cash, equity and potential milestones worth up to $50 million. Enzymatics stated that the acquisition expands its Enzymatics Diagnostics group, adding technology that can provide hospitals, research institutions and other diagnostic providers with a total solution for the detection and assessment of genetic biomarkers. “Enzymatics, which already supplies reagents and kits to approximately 80% of the NGS industry, together with ArcherDx, will bring novel sequencing applications more directly to clinical researchers,” commented Enzymatics President and CEO Jon DiVincenzo. ArcherDx cofounder and CEO Jason Myers, PhD, will join Enzymatics as CSO.
